Author: AtaiBeckley Inc.

Posted Date:

May 12, 2026

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

AtaiBeckley Inc.

May 12, 2026
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

AtaiBeckley Inc.

April 23, 2026
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

AtaiBeckley Inc.

April 8, 2026
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

AtaiBeckley Inc.

March 24, 2026
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

AtaiBeckley Inc.

March 10, 2026
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

AtaiBeckley Inc.

March 6, 2026